Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 16/20 | 0.60 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12359231 | 0.92 | TRPV1 (0.52) | TRPV1TRPM8CYP3A4CYP2C9 | |
| SCHEMBL12359287 | 0.84 | NPC1 (0.48) | TRPV1RAB9A | |
| SCHEMBL1798089 | 0.82 | TRPV1 (0.86) | TRPV1TRPM8CYP3A4CYP2C9 | |
| SCHEMBL1798093 | 0.82 | TRPV1 (0.86) | TRPV1TRPM8CYP3A4CYP2C9 | |
| SCHEMBL1801446 | 0.82 | TRPV1 (0.65) | TRPV1TRPM8CYP3A4CYP2C9TNF | |
| SCHEMBL1801447 | 0.82 | TRPV1 (0.65) | TRPV1TRPM8CYP3A4CYP2C9TNF | |
| SCHEMBL12359235 | 0.82 | TRPV1 (0.54) | TRPV1RAB9A | |
| SCHEMBL12358850 | 0.81 | TRPV1 (0.62) | TRPV1TRPM8CYP3A4CYP2C9TNF | |
| SCHEMBL12359282 | 0.79 | TRPV1 (0.55) | TRPV1RAB9A | |
| SCHEMBL12653103 | 0.78 | MEN1 (0.57) | TRPV1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885TRPM8 229/4885CYP3A4 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.